Comparative Pharmacology
Head-to-head clinical analysis: NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE versus SUDAFED 24 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE versus SUDAFED 24 HOUR.
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE vs SUDAFED 24 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naphazoline is an alpha-adrenergic receptor agonist that causes vasoconstriction of conjunctival blood vessels, reducing redness and edema. Pheniramine is a histamine H1-receptor antagonist that blocks the effects of histamine, reducing itching and allergic symptoms.
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
1-2 drops or sprays in each nostril every 4-6 hours as needed, not to exceed 5-7 days
120 mg orally every 24 hours (extended-release tablet).
None Documented
None Documented
Naphazoline: Terminal elimination half-life approximately 2-3 hours; clinical effects may persist longer due to local vasoconstriction. Pheniramine: Terminal elimination half-life approximately 14-16 hours; appropriate for twice-daily dosing.
Terminal elimination half-life 9-16 hours (mean 11 hours) in adults; prolonged in renal impairment (up to 24-30 hours in severe insufficiency); clinically relevant for dosing interval (every 24 hours)
Naphazoline: Renal excretion of unchanged drug and metabolites accounts for >80% of elimination. Pheniramine: Renal excretion of unchanged drug and metabolites accounts for >90% of elimination, with <5% biliary/fecal elimination.
Renal 70-90% unchanged; minor hepatic metabolism to inactive metabolites; biliary/fecal excretion negligible (<5%)
Category C
Category C
Ophthalmic Antihistamine/Decongestant
Decongestant